WSGR logoWSGR logo

Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.

For more than six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Introducing Neuron, a new platform that streamlines, automates, and digitizes the typical legal processes along a start-up’s journey

Neuron Website
Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

Newsletters
The PTAB Review - June 2022
Alerts
FDA Issues Guidance on Importing Drugs from Canada
Press Releases
Wilson Sonsini Adds Former SEC Fintech Specialist Neel Maitra to Corporate Practice
Leading Matters
Client Highlights
Wilson Sonsini Advises Ledger Investing in $75 Million Series B
On June 22, 2022, Ledger Investing, an InsurTech start-up connecting insurance risk with capital, announced that it has raised $75 million in its Series B funding round led by WestCap, with participation from Teachers’ Venture Growth and Intact Ventures, and previous investors SignalFire, MassMutual Ventures, Allegis Capital, and Accel. Wilson Sonsini Goodrich & Rosati represented Ledger Investing in the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises CellPoint on Acquisition by Galapagos
On June 21, 2022, Galapagos, a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines, announced it has signed a definitive agreement for an all-cash acquisition of CellPoint for an upfront payment of €125 million, with additional milestone payments up to €100 million. CellPoint is dedicated to developing CAR-T therapies at the point-of-care, making these therapies more affordable and accessible to patients. Wilson Sonsini Goodrich & Rosati advised CellPoint on the transaction.
Learn More
Client Highlights
Firm Advises Turntide Technologies on $80 Million Fundraise
On June 15, 2022, Turntide Technologies announced that it has secured $80 million in equity funding, valuing the company at over $1 billion. Turntide develops electrification and sustainable operations technologies, which include energy-efficient motors, dramatically reducing carbon emissions and improving energy savings for building operations, agriculture, equipment, and commercial and industrial vehicles. Wilson Sonsini Goodrich & Rosati advised Turntide on the transaction.
Learn More
Client Highlights
Boehringer Ingelheim Signs Option to Acquire Trutino Biosciences
On June 14, 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced the signing of an option to acquire Trutino Biosciences Inc., a San Diego-based pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Trutino Biosciences in the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises OhmConnect on $55 Million Series D
On June 9, 2022,  OhmConnect, the leading provider of residential energy flexibility, announced it has raised $55 million in its Series D funding round led by ClearSky, Sidewalk Infrastructure Partners (SIP), and TELUS Ventures. Wilson Sonsini Goodrich & Rosati represented OhmConnect in the transaction.
Learn More
Client Highlights
Wilson Sonsini Serves as Lead Counsel in Not Guilty Verdict in $165 Million Health Care Fraud Scheme
On June 13, 2022, New York occupational therapist Mayura Kanekar was found not guilty of federal charges that she had engaged in Medicare fraud, tax evasion, and submission of false claims for the reimbursement of occupational therapy services. After three weeks of trial in the Eastern District of New York, a jury returned a unanimous “not guilty” verdict on all counts of indictment in which Ms. Kanekar and two others were charged. 
Learn More
See More Leading Matters
The Life Sciences Report – June 2022

This latest issue features articles on the firm’s new Boulder office and recent Gateway to Colorado VC roadshow, a collaboration between Deloitte’s Center for Health Solutions and MedTech Innovator to evaluate trends across the medical technology start-up landscape, and life sciences venture financings in which clients participated across the first half and second halves of 2021. It also includes an update on the priority fight between UC and the Broad Institute over CRISPR gene editing patents, articles addressing patented inventions under the patent safe harbor of Section 271(e)(1) and the firm’s partnership with Bakar Labs, and a summary of select recent life sciences client highlights and upcoming events.

Read More
WSGR logo
Copyright © 2022 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.